Atlas Trials

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

Clinical trial NCT03532451 · COMPLETED

Trial details

NCT number
NCT03532451
Sponsor
PrECOG, LLC.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2019-03-22
Primary completion
2020-11-27
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.